ENTITY

Biomarin Pharmaceutical (BMRN US)

60
Analysis
Health CareUnited States
BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin's subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.
more
15 Apr 2016 11:33

Healthcare Observer: Orthopedic Innovation Beyond Large Joint Market Fuels Long-Term Growth

Over the next decade, we expect orthopedic innovation in extremities, robotics, and 3-D printing to be key drivers of growth as fee-for-value...

Logo
206 Views
Share
22 Jan 2016 15:52

Low Odds of U.S. Drug Pricing Reforms Create Favorable Valuations

Democratic presidential candidates' potential drug policy reforms have pressured drug stocks, and ongoing political campaigns are likely to...

Logo
1.5k Views
Share
12 Nov 2015 09:34

Healthcare Observer: As Long-Term Patent Exposure Ebbs, Innovation in Big Pharma Pipelines Support

Pipeline innovation outpacing patent losses represents a core element of the wide moat ratings for most of the Big Pharma firms. Slowing patent...

Logo
327 Views
Share
07 Oct 2015 11:15

Morningstar Healthcare Observer: Biotech Industry Undervalued

The median price/fair value in our biotech universe is 0.87, and in late September valuations fell to their cheapest levels since 2011. While this...

Logo
291 Views
Share
06 Oct 2015 11:03

SoulCycle IPO - Good for your portfolio and your soul?

"Dance party on a bike" - that's how the founders of SoulCycle like to describe their business. SoulCycle is a lifestyle and fitness brand that...

Logo
255 Views
Share
x